Evidence map›Paper›PMID 38378689›Full record

ArticleBreast cancer research : BCR2024

The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [

Amelie Heesch, Alexandru Florea, Jochen Maurer, Pardes Habib, Laura S Werth, Thomas Hansen, Elmar Stickeler, Sabri E M Sahnoun, Felix M Mottaghy, Agnieszka Morgenroth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amelie HeeschDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany. aheesch@ukaachen.de.
Alexandru FloreaDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Jochen MaurerDepartment of Obstetrics and Gynecology, University Hospital RWTH Aachen, 52074, Aachen, Germany.
Pardes HabibDepartment of Neurosurgery, School of Medicine, Stanford University, Stanford, USA.
Laura S WerthDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Thomas HansenDepartment of Obstetrics and Gynecology, University Hospital RWTH Aachen, 52074, Aachen, Germany.
Elmar StickelerDepartment of Obstetrics and Gynecology, University Hospital RWTH Aachen, 52074, Aachen, Germany.
Sabri E M SahnounDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Felix M MottaghyDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Agnieszka MorgenrothDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.

Funding

Deutsche Forschungsgemeinschaft 331065168Deutsche Krebshilfe 70113779Deutsche Krebshilfe 70113780
6 · The paper itself

Abstract

introductionOverexpression of prostate-specific membrane antigen (PSMA) on the vasculature of triple-negative breast cancer (TNBC) presents a promising avenue for targeted endogenous radiotherapy with [

methodsRj:NMRI-Foxn1

resultsTumor volumes were significantly smaller in the single dose (p < 0.001) and fractionated dose (p < 0.001) groups. Tumor growth inhibition rates were 38% (single dose) and 30% (fractionated dose). Median survival was notably prolonged in the treated groups compared to the control groups (31d, 28d and 19d for single dose, fractionated dose and control, respectively). [

conclusionThis study highlights the potential of [

Indexed as

RadioisotopesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDipeptidesHumansMaleMicePositron Emission Tomography Computed TomographyProstateRadiopharmaceuticalsDipeptidesRadioisotopesRadiopharmaceuticalsAnti-angiogenic therapyEndogenous radiotherapyOrthotopic xenograftProstate-specific membrane antigenTriple-negative breast cancer

Identifiers

PMID38378689
PMCPMC10877802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.